Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Cleveland Clinic

Sites in Cleveland, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1321
Shown on this page
12
Current sort
Recently updated
Campus scope
Cleveland Clinic, Cleveland, OH
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Cleveland Clinic, Cleveland, OH. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 313–324 of 1,321 matching trials with a site at Cleveland Clinic, Cleveland, OH.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Not yet recruiting No phase listed Observational

Wearable Technology in Heart Failure Patients

NCT07650669
Site status not listed — check the official record
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2040
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Recruiting Not applicable Interventional

HMB Enriched Amino Acids to Reverse Muscle Loss in Cirrhosis

NCT05166499
Status at this site: Recruiting
View directory record Official record
Conditions
Cirrhosis, Liver
Interventions
Hydroxy Methyl Butyrate, Balanced Amino Acids
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

NCT06744920
Site status not listed — check the official record
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Remibrutinib (Blinded), Placebo, Remibrutinib (Open Label)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
23
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Recruiting Not applicable Interventional

Intraoperative Electrical Stimulation to Improve Nerve Grafting Outcome

NCT06335719
Status at this site: Recruiting
View directory record Official record
Conditions
Facial Paralysis
Interventions
BES, Standard of Care surgery
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

NCT06619236
Site status not listed — check the official record
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer
Interventions
Rina-S, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin (PLD), Gemcitabine
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older · Female only
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
72
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Not yet recruiting No phase listed Observational

Dietary Tracking in Heart Failure

NCT07649148
Site status not listed — check the official record
View directory record Official record
Conditions
Heart Failure, NYHA Class II Heart Failure, NYHA Class III Heart Failure
Interventions
Limiting Ultraprocessed Food (UPF) in Diet
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Comparing Reduction With ESD- Versus APC-TORe

NCT06131281
Status at this site: Recruiting
View directory record Official record
Conditions
Obesity, Roux-en-y Anastomosis Site, Weight Gain
Interventions
E-TORe, c-TORe
Procedure
Lead sponsor
Stephen Firkins
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

NCT05562830
Status at this site: Recruiting
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Zilovertamab vedotin, Pembrolizumab, MK-3120
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
10
States / cities
Orange, California • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

NCT06742996
Status at this site: Recruiting
View directory record Official record
Conditions
Mantle Cell Lymphoma, B Cell Lymphoma
Interventions
Sonrotoclax, Zanubrutinib, Placebo
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT07149857
Status at this site: Recruiting
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cilta-cel, Cyclophosphamide, Induction therapy, Fludarabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
San Francisco, California • Tampa, Florida • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05083169
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Teclistamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 9:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

NCT06385080
Status at this site: Recruiting
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Amivantamab, Pembrolizumab, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
15
States / cities
La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 9:03 PM EDT

About this Cleveland Clinic institution page

What this page lists
ClinicalTrials.gov records that list Cleveland Clinic in Cleveland, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.